149 related articles for article (PubMed ID: 36241525)
1. Incidence, prevalence, and treatment patterns in metastatic hormone-sensitive prostate cancer in Spain: ECHOS study.
de Velasco Oria de Rueda G; Plata Bello AC; Landeira M; Mateo M; Anguita P; Pranzo A; Snijder R; Garnham A; Hernández I
Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):557-564. PubMed ID: 36241525
[TBL] [Abstract][Full Text] [Related]
2. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
[TBL] [Abstract][Full Text] [Related]
3. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Lambert E; Hollebosch S; van Praet C; Van Bruwaene S; Duck L; De Roock W; van Wambeke S; Ghysel C; Ameye F; Schatteman P; Vandenbroucke F; Sautois B; Baekelandt F; Ost D; Fransis K; Filleul B; Remondo C; Wynendaele W; Bamelis B; Logghe P; Vergauwe E; Denies E; Joniau S; Lumen N
Acta Clin Belg; 2022 Dec; 77(6):897-905. PubMed ID: 34789066
[TBL] [Abstract][Full Text] [Related]
5. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
[TBL] [Abstract][Full Text] [Related]
6. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
[TBL] [Abstract][Full Text] [Related]
7. Hormone naïve metastatic prostate cancer: How to treat it?
Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
[TBL] [Abstract][Full Text] [Related]
8. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
[TBL] [Abstract][Full Text] [Related]
9. Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics.
Lokeshwar SD; Choksi AU; Haltstuch D; Rahman SN; Press BH; Syed J; Hurwitz ME; Kim IY; Leapman MS
World J Urol; 2023 Aug; 41(8):2007-2019. PubMed ID: 37160450
[TBL] [Abstract][Full Text] [Related]
10. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.
Dodkins J; Nossiter J; Cook A; Payne H; Clarke N; van der Meulen J; Aggarwal A
Eur Urol Oncol; 2024 Feb; 7(1):14-24. PubMed ID: 37380578
[TBL] [Abstract][Full Text] [Related]
11. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.
Matsumura N; Fujita K; Nishimoto M; Minami T; Tahara H; Yoshimura K; Uemura H
World J Urol; 2023 Aug; 41(8):2063-2068. PubMed ID: 36040500
[TBL] [Abstract][Full Text] [Related]
12. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia.
Goebell PJ; Raina R; Chen S; Rege S; Shah R; Grossman JP; Waldeck AR
Future Oncol; 2024 May; 20(14):903-918. PubMed ID: 38353055
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
15. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.
Borque-Fernando A; Calleja-Hernández MA; Cózar-Olmo JM; Gómez-Iturriaga A; Pérez-Fentes DA; Puente-Vázquez J; Rodrigo-Aliaga M; Unda M; Álvarez-Ossorio JL
Actas Urol Esp (Engl Ed); 2023 Mar; 47(2):111-126. PubMed ID: 36720305
[TBL] [Abstract][Full Text] [Related]
16. Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population.
Gupta A; Hussain SM; Sonthwal N; Chaturvedi H
J Cancer Res Ther; 2021; 17(2):389-392. PubMed ID: 34121682
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Ito T; Grant L; Duckham BR; Ribbands AJ; Gater A
Adv Ther; 2018 Dec; 35(12):2186-2200. PubMed ID: 30415297
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Xu L; Pachynski RK
Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
